sovicell
About Sovicell
Products
Contract Services
Science & Technology
News & Events
Career
Protein Binding
- PPB
- Full plasma
- HSA
- RSA
- AGP / AAG
Brain Tissue Binding
Brain-to-Plasma Distribution
Microsomal Binding
Intestinal Absorption
Trusted ADMET
products & services

News

22/03/20173B Pharmaceuticals and Sovicell introduce a novel service offering for plasma protein binding analysis

Products

Ready-to-use assay systems for DMPK and ADMET studies

Factsheet Download

A fast high throughput assay for predicting the binding of drugs to plasma proteins by measuring their affinity simultaneously to HSA (human serum albumin) and AGP (α1-acid glycoprotein) in a single assay.

Features
  • Ready-to-use 96-well microtiter plates carrying TRANSIL beads with HSA and AGP immobilized in random orientation to expose all binding sites. The assay is designed to conveniently measure HSA and AGP binding of drugs and accurately predict plasma proteins binding of drugs. HSA and AGP data are combined in a physiological ratio.
  • Includes spreadsheet, facilitating manipulation of statistical parameters and calculation of final results.
  • Designed for automated liquid handlers or manual pipetting.
Benefits
  • TRANSIL beads are integrated into 96-well microtiter plates to enable easy handling.
  • One plate can be used to measure HSA and AGP binding of up to 12 compounds.
  • Only 12 minutes assay incubation time.
  • Rapid compound quantification due to immobilized plasma proteins (e.g. injection via RapidFire™).
  • Highly reproducible results and robust correlation with conventional dialysis technique.
Background and Technical Information

Human serum albumin (HSA) is the most abundant protein in blood plasma. It is synthesized in the liver and concentrations in healthy subjects normally range between 35 and 60 g/L with an average of 42 g/L. HSA comprises 60% of the total plasma proteins. Its main physiological function is to bind and carry endogenous anions, with long-chain fatty acids. Two high affinity binding sites have been proposed in subdomains IIA (also known as Sudlow’s site I or warfarin site) and IIIA (also known as Site II or benzodiazepine site) of HSA. These comprise highly elongated hydrophobic pockets with charged lysine and arginine residues near the surface that interact with polar ligand parts. In contrast to AGP(α1-acid glycoprotein),, HSA blood levels are much more stable. Hyperalbuminemia (HSA > 55 g/L) is seldom seen in the absence of dehydration whereas hypoalbuminemia is the more common condition resulting from malnutrition or liver disease with serum albumin levels dropping to 20-23 g/L.

The resolution of conventional methods (e.g. dialysis, ultrafiltration) is limited, particularly when examining drugs that are highly bound to plasma proteins. These conventional methods require highly sensitive analytical techniques that exhibit a linear range of more than two orders of magnitude or the use of highly pure radiolabeled compounds to resolve plasma protein binding of compounds with fu values less than 0.01. Given those constraints for the determination of plasma protein binding, the TRANSILXL HSA and TRANSILXL AGP Assay kits were developed and validated employing a novel method that overcomes these limitations and addresses the problem of varying HSA and AGP levels. To overcome the analytical limitations, when examining drugs that are highly bound to plasma proteins, the TRANSILXL PPB Binding kit determines a pseudo KD value to HSA and AGP by titrating different subphysiological concentrations of HSA and AGP (at a constant physiological ratio) against a constant drug concentration.

website by
College Hill - Life Sciences
Sovicell GMBH, Deutscher Platz 5b, 04103 Leipzig, Germany    t: +49 341 520 44 0   f: +49 341 520 44 12